| Hormone treatment group (n = 21) | No treatment group (n = 20) | p-value |
---|---|---|---|
Age* (years) | 47.14 (4.1) | 49.35 (2.7) | 0.049 |
Age < 45 years | 5 (24%) | 0 (0%) |  |
Age ≥ 45 years | 16 (76%) | 20 (100%) |  |
BMI* (kg/m2) | 26.40 (4.9) | 23.96 (2.5) | 0.056 |
Marital status | |||
Married | 17 (81%) | 15 (75%) | Â |
Single | 4 (19%) | 5 (25%) | Â |
Parity | |||
Nulliparous | 9 (43%) | 9 (45%) | Â |
Multiparous | 12 (57%) | 11 (55%) | Â |
Underlying disease | |||
Hypertension | 2 (9%) | 3 (15%) | Â |
Dyslipidemia | 1 (5%) | 1 (5%) | Â |
Primary indication for surgery | |||
Myoma uteri | 6 (29%) | 11 (55%) | Â |
Adenomyosis | 4(19%) | 6 (30%) | Â |
Endometriosis, endometrioma | 10(48%) | 4 (20%) | Â |
BRCA mutation | 0 | 1 (5%) | Â |
Endometrial hyperplasia | 0 | 1 (5%) | Â |
CIN III | 1 (5%) | 0 | Â |
FSH** (IU/L) | 10.59 (6.84–36.64) | 11.86 (4.81–28.30) | 0.735 |
CTX** (ng/ml) | 0.21 (0.17–0.35) | 0.24 (0.19–0.34) | 0.273 |
P1NP** (ng/ml) | 37.97 (26.09–54.62) | 42.11 (35.26–72.57) | 0.112 |